

SEQUENT SCIENTIFIC LIMITED

### STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2017

							(Rs. in Lakhs)
					Year to date	Year to date	
	Particulars			Corresponding 3	figure for	figure for	
	r articulars	3 months	Preceding 3	months ended in	current period	previous	Previous year
		ended	months ended	previous period	ended	period ended	ended
		31-Dec-2017	30-Sep-2017	31-Dec-2016	31-Dec-2017	31-Dec-2016	31-Mar-2017
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Revenue from operations (Refer note 4)	2,672.07	2,643,83	3,024.77	8,044.09	6,686.22	9,453.33
11	Other income	448.67	1,025.14	358.74	1,917.64	1,204.83	1,906.74
III	Total income (I+II)	3,120.74	3,668.97	3,383.51	9,961.73	7,891.05	11,360.07
***	Total medite (1711)	3,120.74	3,000.37	3,363.51	3,361.73	7,031.05	11,360.07
IV	Expenses						
	(a) Cost of materials consumed	368.65	1,013.89	947.80	1,963.59	3,414.75	4,216.60
	(b) Purchases of stock-in-trade	1,346.10	1,358.03	1,447.90	3,966.16	1,503.49	2,811.90
	(c) Changes in inventories of finished goods, stock-in-trade and work-	(144.80)	137.40	40.40	(7.14)	40.82	(44.37
	in-progress	(111.00)	107.40	276370)	2250000000		
	(d) Excise duty on sale of goods			86.04	122.92	280.06	381.82
	(e) Conversion and processing charges	414.20	105.27	258.63	757.71	724.59	991.52
	(f) Employee benefits expense	239.61	399.23	568.77	1,002.43	1,676.21	1,790.16
	(h) Finance costs	6.41	7.24	35.51	21.81	33.30	42.30
	(h) Depreciation and amortisation expense	95.14	74.07	138.02	247.27	225,41	325,18
	(i) Other expenses	625.00	226.13	575.12	1,642.61	1,310,26	2.093.09
	Total expenses (IV)	2,950.31	3,321.26	4,098.19	9,717.36	9,208.89	12,608.20
	Total expenses (iv)	2,550,51	3,321.20	4,030.13	5,717.30	3,200.03	12,600.20
v	Profit/(loss) from continuing operations before tax and	170.43	347.71	744.50	244.37	44.047.041	
•	exceptional item (III-IV)	170.43	347.71	(714.68)	244.37	(1,317.84)	(1,248.13)
vı	Exceptional items						
	Liceptonial items	-			-		
VII	Profit/(loss) from continuing operations before tax (V-VI)	170.43	347.71	(714.68)	244.37	(1,317.84)	(1,248.13)
VIII	Tax expense						
	(a) Current tax	52.15	-		52.15		
	(b) Deferred tax				250		
	Total tax expense (VIII)	52.15			52.15		
x	Profit / (Loss) from continuing operation after tax (VII-VIII)	118.28	347.71	744.00	(326.103)		
^	Profit (Loss) from continuing operation after tax (VII-VIII)	110.20	347.71	(714.68)	192.22	(1,317.84)	(1,248.13)
(	Profit/(Loss) from discontinued operation	(189.25)	872.79	646.83	1,510.51	993.75	1,246.93
	Tax expense of discontinued operation	362.73	-	2	362.73		
- 1	Profit/(Loss) from discontinued operation after tax (X)	(551.98)	872.79	646.83	1,147.78	993.75	1,246.93
a	Profit / (loss) for the period (IX+X)	(433.70)	1,220.50	(67.85)	1,340.00	(324.09)	(1.20)
(II	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
		4.70					12/20
	(a) Re-measurements of defined benefits plans	1.70	1.80	17.38	5.40	52.13	7.00
	(b) Fair value gain / (loss) from investment in equity instruments	(2,062.80)	(3,802.80)	1,865.21	(9,096.40)	(865.58)	339.10
- 1	Total other comprehensive income for the period (XII)	(2,061.10)	(3,801.00)	1,882.59	(9,091.00)	(813.45)	346.10
CIII	Total comprehensive income for the period (XI+XII)	(2,494.80)	(2,580.50)	1,814.74	(7,751.00)	(1,137.54)	344.90
αv	Earnings per equity share: (Face value of Rs. 2 each) (not-						
	annualised)						
	- for continuing operations						
	(1) Basic ( in Rs.)	0.05	0.14	(0.30)	0.08	(0.55)	(0.52)
	(2) Diluted (in Rs.)	0.05	0.14	(0.30)	0.08	(0.55)	(0.52)
	Selection School Add				(5876)	3.7.2.4	1,000
	- for discontinued operations						
- 1	(1) Basic ( in Rs.)	(0.23)	0.36	0.27	0.47	0.41	0.52
	(2) Diluted (in Rs.)	(0.23)	0.36	0.27	0.47	0.41	0.52
	- for continuing and discontinued executions						
- 1	- for continuing and discontinued operations	10.13					geran.
	(1) Basic (in Rs.)	(0.18)	0.50	(0.03)	0.55	(0.14)	(0.00)
	(2) Diluted (in Rs.)	(0.18)	0.50	(0.03)	0.55	(0.14)	(0.00)
1							

- Notes:

  1 The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 09 February 2018. The statutory auditors have carried out limited review of the financial results for the quarter and nine months ended 31 December 2017.
- 2 The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- 2. The Company has only one reportable segment viz. Pharmaceuticals, Accordingly, no separate disclosure of segment information has been made.
  In line with the Company's focus on value creation in Animal Healthcare, the Board of Directors of the Company had earlier approved a scheme for demerger of Human API Business, subject to the approval from the regulatory authorities as may be necessary. The Company's application is pending with the National Company Law Tribunal (INCLT) Mumbai Bench. Under the above scheme, (which envisages an appointed date of 01 October 2017), the Company's Human API Business is proposed to be demerged into a new listed entity, During the quarter ended 31 December 2017, the shareholders of the Company in their meeting convened on 26 December 2017 pursuant to the direction of the NCLT, have approved the scheme of demerger. The Human API business has been considered as discontinued operations in these results.

Particulars	3 months ended 31-Dec-2017	Preceding 3 months ended 30-Sep-2017	Corresponding 3 months ended in previous period 31-Dec-2016	Year to date figure for current period ended 31-Dec-2017	Year to date figure for previous period ended 31-Dec-2016	(Rs. In Lakhs)  Previous year ended 31-Mar-2017
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Total Revenue	6,577.56	8,333.93	7,510.85	23,373.16	22,378,75	29,870.63
Total Expenses	6,766.81	7,461.14	6,864.02	21,862.65	21,385.00	28.623.70
Profit/ (Loss) before exceptional item and tax	(189.25)	872.79	646.83	1,510.51	993.75	1,246,93
Exceptional items						
Profit (Loss) before tax	(189.25)	872.79	646.83	1,510.51	993.75	1,246.93
Tax expense of discontinued operation	362.73			362.73		
Profit/ (Loss) for the period	(551.98)	872.79	646.83	1,147.78	993.75	1,246.93

- 4 Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the nine months ended 31 December 2017 included excise duty upto 30 June 2017. Accordingly, revenue from operation for the quarter and nine months ended 31 December 2017 are not comparable with those of the previous periods presented.
- 5 During the previous quarter, the Company has sold investment in one of the subsidiary company, Naari Pharma Private Limited and recognised a profit of Rs. 382.88 lakhs under 'Other Income'.
- 6 Tax expenses has been accrued during the current quarter based on estimated Minimum Atternate Tax applicable to the entity and has been split between continuing and discontinued operations based on book profits from the respective operations.
- 7 The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited

Manish Gupta Managing Director



Place : Thane Date: 09 February 2018



### SEQUENT SCIENTIFIC LIMITED

## STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND PERIOD ENDED 31 DECEMBER 2017

	(Rs. i									
	Particulars	3 months ended 31-Dec-2017	Preceding 3 months ended 30-Sep-2017	Corresponding 3 months ended in the previous period 31-Dec-2016	Year to date figures for the current period ended 31-Dec-2017	Year to date figures for the previous period ended 31-Dec-2016	Previous year ended 31-Mar- 2017			
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED			
-1	Revenue from operations ( Refer note 6)	22,414.16	21,406.97	20,896.85	63,244.32	48,867.99	68,900.65			
11	Other income	343.80	660.14	546.19	1,366.24	1,099.65	1,107.70			
III	Total Income (I+II)	22,757.96	22,067.11	21,443.04	64,610.56	49,967.64	70,008.35			
IV	[77] [20] [40] [40] [40] [40] [40] [40] [40] [4									
	(a).Cost of materials consumed	7,834.58	7,495.13	8,226.96	23,752.48	19,166.15	27,575.81			
	(b).Purchase of stock-in-trade	5,632.81	3,961.91	1,285.59	12,605.60	5,448.52	8,844.47			
	(c).Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,454.20)	1,475.00	1,635.80	(804.24)	680.19	(1,018.37)			
	(d) Excise duty on sale of goods	-		126.28	161.02	386.77	543.72			
	(e).Employee benefits expense	3,001.41	2,806.03	2,953.23	8,489.03	7,950.91	10,622.36			
	(f). Finance costs	790.31	724.33	817.96	2,284.59	2,108.33	2,833.91			
	(g).Depreciation and amortisation expense (h).Other expense	1,172.70	997.62	1,292.82	3,181.24	3,057.59	4,007.30			
	Total expenses	5,720.46 22,698.07	3,796.81 21,256.83	5,962.60 22,301.24	13,819.53 63,489.25	13,273.97 52,072.43	17,769.91			
.,		100000000000000000000000000000000000000	59027011	100000000000000000000000000000000000000	62 2020 2		71,179.11			
٧	Profit/(loss) from continuing operations before tax and exceptional item (III-IV)	59.89	810.28	(858.20)	1,121.31	(2,104.79)	(1,170.76)			
VI	Exceptional items	5	-	-	-	-				
VII	Profit/(loss) from continuing operations before tax (V-VI)	59.89	810.28	(858.20)	1,121.31	(2,104.79)	(1,170.76)			
VIII	N.E. (A.C.) (1886) (188									
	(a).Current tax	482.47	438.10	223.48	1,143.87	499.68	706.50			
	(b).Deferred tax	(119.70)	(55.30)	(71.30)	(205.70)	(68.14)	(376.60)			
	(c).Prior period taxes	¥.	14.1	(*)		-	(382.64)			
	Total tax expenses	362.77	382.80	152.18	938.17	431.54	(52.74)			
IX	Profit/(loss) from continuing operations after tax (VII-VIII)	(302.88)	427.48	(1,010.38)	183.14	(2,536.33)	(1,118.02)			
	Profit/(loss) from discontinued operation	(182.30)	880.92	(34.45)	864.78	(148.06)	(509.24)			
	Gain on disposal of assets/settlement of liabilities attributable to the discontinuing operations	-	1,745.50		1,745.50		5.75			
	Tax expense of discontinued operation	362.73		12.82	362.73	4.26	11.44			
X	Profit/(loss) from discontinued operations after tax	(545.03)	2,626.42	(47.27)	2,247.55	(152.32)	(520.68)			
XI	Profit/(loss) for the period (IX+X)	(847.91)	3,053.90	(1,057.65)	2,430.69	(2,688.65)	(1,638.70)			
XII	Other comprehensive income									
	Items that will not be reclassified to profit or loss  (a).Re-measurement gains/(losses) on defined benefits plans	110	1.00	44.00	(4.20)	40.00	44.40			
	(b).Fair value gain / (loss) from investment in equity instruments	(2,062.80)	(3,802.80)	14.00 1,865.20	(9,096.40)	42.30 (865.60)	(14.40) 339.10			
	Items that may be reclassified to profit or loss	(2,002.00)	(3,602.60)	1,003.20	(9,030.40)	(003.00)	339.10			
	(a).Exchange differences on translation of foreign operations	(144.38)	95.38	29.46	82.50	(71.78)	(348.63)			
	(b).Exchange differences on net investment in foreign operations	(439.31)	245.96	237.25	(292.15)	237.25	(407.87)			
	Total other comprehensive income	(2,645.39)	(3,460.26)	2,145.91	(9,307.35)	(657.83)	(431.80)			
XIII	Total comprehensive income for the period (XI+XII)	(3,493.30)	(406.36)	1,088.26	(6,876.66)	(3,346.48)	(2,070.50)			
	Profit for the period attributable to:		, , , , , ,			(-,	(2)			
	- Owners of the Company	(1,129.01)	2,923.90	(524.55)	2,018.59	(2,064.65)	(1,382.40)			
	- Non-controlling interests	281.10	130.00	(533.10)	412.10	(624.00)	(256.30)			
	Other comprehensive income for the period attributable to:				13 41	***************************************				
	- Owners of the Company	(2,596.19)	(3,492.56)	2,159.05	(9,357.75)	(650.25)	(298.20)			
	- Non-controlling interests	(49.20)	32.30	(13.14)	50.40	(7.58)	(133.60)			
	Total comprehensive income for the period attributable to:									
	- Owners of the Company	(3,725.20)	(568.66)	1,634.50	(7,339.16)	(2,714.90)	(1,680.60)			
	- Non-controlling interests	231.90	162.30	(546.24)	462.50	(631.58)	(389.90)			
	Earnings per equity share: (face value of Rs. 2 each) (not annualised) - for continuing operations									
	(1) Basic (in Rs.)	(0.24)	0.13	(0.34)	(0.25)	(1.06)	(0.77)			
	(2) Diluted (in Rs.)	(0.24)	0.13	(0.34)	(0.25)	(1.06)	(0.77)			
	-for discontinued operations				/	,,	,,			
	(1) Basic (in Rs.)	(0.23)	1.08	0.13	1.08	0.19	0.19			
	(2) Diluted (in Rs.)	(0.23)	1.07	0.13	1.07	0.19	0.19			
	- for continuing and discontinued operations					2				
	(1) Basic ( in Rs.)	(0.47)	1.21	(0.21)	0.83	(0.87)	(0.58)			
	(2) Diluted (in Rs.)	(0.47)	1.20	(0.21)	0.82	(0.87)	(0.50)			
	See accompanying notes to the financial results	(0.47)	1.20	(0.21)	0,02	(0.87)	(0.58)			





### SEQUENT SCIENTIFIC LIMITED

Notes:
1. The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 09 February 2018. The statutory auditors have carried out limited review of the financial results for the quarter and nine months ended 31 December 2017.

2. With effect from 01 April, 2017 the Chief Operating Decision Maker (CODM) reviews the operations as one segment "Pharmaceuticals". Accordingly the segment information for earlier periods have been restated in line with provisions of Ind AS 108 "Operating Segments".

3. Information on Standalone Results:						(Rs in Lakhs)
Particulars	3 months ended 31-Dec-2017	Preceding 3 months ended 30-Sep-2017	Corresponding 3 months ended in the previous period 31-Dec-2016	Year to date figures for the current period ended 31-Dec-2017	Year to date figures for the previous period ended 31-Dec-2016	Previous year ended 31-Mar- 2017
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Revenue from operations - Continuing operations	2,672.07	2,643.83	3,024.77	8,044.09	6,686.22	9,453.33
Profit/ (Loss) before tax - Continuing operations	170.43	347.71	(714.68)	244.37	(1,317.84)	(1,248.13)
Profit/ (Loss) after tax - Continuing operations	118.28	347.71	(714.68)	192.22	(1,317.84)	(1,248.13)
Profit/ (Loss) before tax - Discontinued operations	(189.25)	872.79	646.83	1,510.51	993.75	1,246.93
Profit/ (Loss) after tax - Discontinued operations	(551.98)	872.79	646.83	1,147.78	993.75	1,246.93
Total comprehensive income	(2,494.80)	(2,580.50)	1,814.74	(7,751.00)	(1,137.54)	344.90

4a. In line with the Company's focus on value creation in Animal Healthcare, the Board of Directors of the Company had earlier approved a scheme for demerger of Human API Business, subject to the approval from the regulatory authorities as may be necessary. The Company's application is pending with the National Company Law Tribunal (NCLT) Mumbal Bench. Under the above scheme, (which envisages an appointed and of 01 October 2017), the Company's Human API Business is proposed to be demerged into a new listed entity. During the quarter ended 31 December 2017, the shareholders of the Company in their meeting convened on 26 December 2017 pursuant to the direction of the NCLT, have approved the scheme of demerger. The Human API business has been considered as discontinued operations in these results.

4b. During the previous quarter, consequent to the approval of Board of Directors of the Company and shareholders received vide postal ballot dated 24 March 2017 for the divestment of woman healthcare business, the company has sold / transferred the business to Tenshi Life Science Private Limited. Gain on sale of business amounting to Rs. 1745.50 Lakhs is recognised and disclosed under discontinued operations.

The results relating to discontinued business are as follows:

Particulars	3 months ended 31-Dec-2017	Preceding 3 months ended 30-Sep-2017	Corresponding 3 months ended in the previous period 31-Dec-2016	Year to date figures for the current period ended 31-Dec-2017	Year to date figures for the previous period ended 31-Dec-2016	Previous year ended 31-Mar- 2017
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Total Revenue	6,593.46	8,349.83	8,968.95	25,169,16	27,466,90	36,761,09
Total Expenses	6,775.76	7,468,91	9,003,40	24,304,38	27.614.96	37,270.33
Profit/ (Loss) before exceptional item and tax	(182.30)	880.92	(34.45)	864.78	(148.06)	(509.24)
Exceptional items		-	-		-	
Profit/ (Loss) before tax	(182.30)	880.92	(34.45)	864.78	(148.06)	(509.24)
Gain on disposal of assets/settlement of liabilities attributable to the discontinuing operations		1,745.50	-	1,745.50		
Tax Expense	362.73	-	12.82	362.73	4.26	11.44
Profit/ (Loss) for the period	(545.03)	2,626.42	(47.27)	2,247.55	(152.32)	(520.68)

5. Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the nine months ended 31 December 2017 included excise duty upto 30 June 2017. Accordingly, revenue from operation for the quarter and nine months ended 31 December 2017 are not comparable with those of the previous periods presented.

6.Tax expenses has been accrued during the current quarter based on estimated Minimum Alternate Tax applicable to the entity and has been split between continuing and discontinued operations based on book profits from the respective operations.

7. The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

Place : Thane Date : 09 February 2018

For Sequent Scien

Manish G Managing Di CIEN

0

Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru - 560 001 Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

# INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

## TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of SEQUENT SCIENTIFIC LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2017 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 3. The Statement includes the results of the following entities:
  - i) Alivira Animal Health Australia Pty Ltd;
  - ii) Alivira Animal Health Limited, Ireland;
  - iii) Alivira Animal Health Limited, India;
  - iv) Alivira Saude Animal Brasil Participacoes Ltda;
  - v) Alivira UA Limited;
  - vi) Comercial Vila Veterinaria de Lleida S.L;
  - vii) Elysian Life Sciences Private Limited;
  - viii) Fendigo BV;
  - ix) Fendigo SA;
  - x) Interchange Veterinária Indústria E Comércio Ltda;
  - xi) Laboratorios Karizoo, S.A;
  - xii) Laboratorios Karizoo, S.A. De C.V. (Mexico);
  - xiii) N-Vet AB;
  - xiv) Naari Pharma Private Limited;
  - xv) Phytotherapic Solutions S.L;
  - xvi) Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
  - xvii) SeQuent Antibiotics Private Limited;
  - xviii) SeQuent Global Holdings Limited;
  - xix) SeQuent Penems Private Limited;



- xx) SeQuent Pharmaceuticals Private Limited;
- xxi) SeQuent Research Limited;
- xxii) Sequent Scientific Pte. Ltd;
- xxiii) Topkim-Topkapi Ilac Premiks San. ve Tic. A.S;
- xxiv) Vila Viña Participacions S.L;
- 4. Based on our review conducted as stated above and based on the consideration of the review reports of the other auditors referred to in paragraph 5 below, and except for the possible effects of the matter described in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. In respect of continuing operations, we did not review the interim financial results of ten subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs.15,180.11 lakhs and Rs.40,028.23 lakhs for the quarter and nine months ended December 31, 2017, respectively, and total profit after tax of Rs.1,305.86 lakhs and Rs.3,380.59 lakhs and total comprehensive income of Rs.1,305.86 lakhs and Rs.3,380.59 lakhs for the quarter and nine months ended December 31, 2017, respectively, as considered in the consolidated unaudited financial results.

In respect of discontinued operations, we did not review the interim financial results of one subsidiary included in the consolidated financial results, whose interim financial statements reflect total revenues of Rs.1,755.94 lakhs for the quarter ended June 30, 2017, and total net loss after tax of Rs.755.60 lakhs and total comprehensive loss of Rs.762.88 lakhs for the quarter ended June 30, 2017, as considered in the consolidated unaudited financial results.

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

6. In respect of continuing operations, the consolidated unaudited financial results includes the interim financial results of eleven subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs.1,068.92 lakhs and Rs.2,750.86 lakhs for the quarter and nine months ended December 31, 2017, respectively, and total loss after tax of Rs.513.85 lakhs and Rs.617.49 lakhs and total comprehensive loss of Rs.513.85 and Rs.615.21 lakhs for the quarter and nine months ended December 31, 2017, respectively, as considered in the consolidated unaudited financial results.

In respect of discontinued operations, the consolidated unaudited financial results includes the interim financial results of one subsidiary which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. Nil for the quarter and nine months ended December 31, 2017, and total profit after tax of Rs.6.95 lakhs and Rs.7.49 lakhs and total comprehensive income of Rs.6.95 and



Rs.7.49 lakhs for the quarter and nine months ended December 31, 2017, respectively, as considered in the consolidated unaudited financial results.

For **DELOITTE HASKINS & SELLS** 

Chartered Accountants (Firm's Registration No. 008072S)

Sathya P. Koushik

Partner

(Membership No. 206920)

Bangalore, February 09, 2018 SPK/JKS/2018

# Sequent

### SEQUENT SCIENTIFIC LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND PERIOD ENDED 31 DECEMBER 2017

	(Re. in								
	Particulars	3 months ended 31-Dec-2017	Preceding 3 months ended 30-Sep-2017	Corresponding 3 months ended in the previous period 31-Dec-2016	Year to date figures for the current period ended 31-Dec-2017	Year to date figures for the previous period ended 31-Dec-2016	Previous year ended 31-Mar- 2017		
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED		
	enue from operations ( Refer note 6)	22,414,16	21,406.97	20,896.85	63,244.32	48,867.99	68,900 65		
	er income	343 80	660_14	546,19	1,366.24	1,099,65	1,107,70		
1000	al Income (Hil)	22,757,96	22,067.11	21,443,04	64,610,56	49,967.64	70,008.35		
100000	enses								
	Cost of materials consumed	7,834.58	7,495,13	8,226.96	23,752,48	19,166.15	27,575,81		
	Purchase of slock-in-trade	5,632,81	3,961.91	1,285,59	12,605,60	5,448.52	8,844,47		
Victory and	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,454.20)	1,475.00	1,635,80	(804.24)	680,19	(1,018:37		
100000	Excise duty on sale of goods	0.63		126.28	161.02	385,77	543,72		
200	mplayee benefits expense	3,001.41	2,806 03	2,953.23	8,489 03	7,950.91	10,622 36		
	inance costs	790.31	724,33	817.96	2,284,59	2,108.33	2,833,91		
975,555	depreciation and amortisation expense Other expense	1,172,70	997.62	1,292.82	3,181,24	3,057,59	4,007.30		
1.0	I expense	5,720,46	3,796.81	5,962,60	13,819,53	13,273.97	17,769.91		
1000		22,698.07	21,256,83	22,301.24	63,489,25	52,072,43	71,179.11		
V Profi	it/(loss) from continuing operations before tax and exceptional item (III-IV)	59,89	810,28	(858.20)	1,121,31	(2,104,79)	(1,170,76		
VI Exce	ptenal items						-		
VII Profi	V(loss) from continuing operations before tax (V-VI)	59,89	810,28	(858.20)	1,121,31	(2,104.79)	(1,170.76		
/III Tax e	expense				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	44,220,23	(1,110.70		
(a).C	urrent lax	482.47	438.10	223.48	1,143.87	499.68	706,50		
(b) D	eferred tax	(119.70)	(55.30)	(71.30)	(205.70)	(68,14)	(376.60		
(c) Pr	rior period taxes	14		. 1		34313.36	(382.64)		
Total	tax expenses	362.77	382.80	152.18	938.17	431,54	(52.74		
X Profit	t/(loss) from continuing operations after tax (VB-VIII)	(302.88)	427.48	(1,010.38)	183,14	(2,536,33)	(1,118.02		
Profit	(loss) from discontinued operation	(182.30)	680.92	(34.45)	864,78	(148.06)	(509.24)		
Gain	on disposal of assets/settlement of liabilities attributable to the discontinuing operations	3.1	1,745.50	*	1,745.50	(40)	X10000000		
Tax e	expense of discontinued operation	362.73		12 82	362 73	4.26	11.44		
Profit	((loss) (rom discontinued operations after tax	(545.03)	2,626,42	(47.27)	2,247.55	(152.32)	(520.68		
() Profit	U(loss) for the period (IX+X)	(847,91)	3,053.90	(1,057.65)	2,430.69	(2,688,65)	(1,636.70		
(II Olher	r comprehensive income	340,000,000		Circonoosa	-,	(=,===,	(1,550,15		
items	that will not be reclassified to profit or loss								
(a).Re	e-measurement gains/(losses) on defined benefits plans	1,10	1.20	14,00	(1.30)	42.30	(14.40)		
(b) Fa	ir value gain / (loss) from investment in equity instruments	(2,052.60)	(3,802.80)	1,865.20	(9,096.40)	(865.60)	339.10		
Items	that may be reclassified to profit or loss		TEST PER CONTROL OF THE						
(a).Ex	change differences on translation of foreign operations	(144.38)	95,38	29.46	82.50	(71.78)	(346.63)		
(b).Ex	change differences on net investment in foreign operations	(439.31)	245 96	237,25	(292.15)	237.25	(407 87		
Total	other comprehensive income	(2,645,39)	(3,460.26)	2,145.91	(9,307.35)	(657.03)	(431.50)		
III Total	comprehensive income for the pariod (XI+XII)	(3,493.30)	(406,36)	1,088.26	(6,876.66)	(3,346,48)	(2,070,50)		
110	for the period attributable to:								
100	ers of the Company	(1,129.01)	2,923 90	(524,55)	2,018,59	(2,064.65)	(1,382.40)		
	controlling interests	281_10	130 00	(533,10)	412 10	(624.00)	(256.30)		
	comprehensive income for the period attributable to:					1,000,000			
	ers of the Company	(2,596 19)	(3,492 56)	2,159,05	(9,357.75)	(650.25)	(298.20)		
23,700	-controlling interests	(49 20)	32.30	(13.14)	50,40	(7.58)	(133.60)		
	comprehensive income for the period attributable to:				^	1.000.00			
U	ers of the Company	(3,725.20)	(568.66)	1,634,50	(7,339.16)	(2,714.90)	(1,680,60)		
	controlling interests	231.90	162 30	(546.24)	462,50	(631,58)	(389.90)		
	ngs per equity share: (face value of Rs. 2 each) (not annualised) onlinuing operations					E: N			
	sic (in Rs.)	(0.24)	0.13	(0,34)	(0.25)	(1.00)			
(2) Dih	uted (in Rs.)	(0.24)	0.13	(0.34)	(0.25)	(1.06)	(0.77)		
- for di	iscontinued operations	20,000	9,13	(may)	(0.20)	(1,00)	(0,77)		
(1) Bas	sic (in Rs.)	(0.23)	1.08	0.13	1.08	0.19	0 19		
(2) Dilu	uted (in Rs.)	(0 23)	1.07	0,13	1.07	0.19	0.19		
- for ec	ontinuing and discontinued operations	,/		5,.0	,,	0.19	0.19		
(1) Bas	sic (in Rs.)	(0_47)	1.21	(0.21)	0.83	(0.87)	(0.58)		
(2) Dilu	uted (in Rs.)	(0.47)	1.20	(0.21)	0.82	(0.87)	(0.56)		
less.	companying notes to the financial results			\·/	1,00	10.073	[4,29]		





## Sequent

### SEQUENT SCIENTIFIC LIMITED

1. The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 09 February 2018. The statutory auditors have carried out limited review of

2. With effect from 01 April, 2017 the Chief Operating Decision Maker (CODM) reviews the operations as one segment "Pharmaceuticals". Accordingly the segment information for earlier periods have been restated in line with provisions of Ind AS 108 "Operating Segments".

3. Information on Standalone Results:

Particulars	3 months ended 31-Dec-2017	Preceding 3 months ended 30-Sep-2017	Corresponding 3 months ended in the previous period 31-Dec-2016	Year to date figures for the current period ended 31-Dec-2017	Year to date figures for the previous period ended 31-Dec-2016	Previous year ended 31-Mar- 2017	
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
Revenue from operations - Continuing operations	2,672.07	2,643.63	3,024,77	8.044.09	6.686.22	9,450.33	
Profit/ (Loss) before tax - Continuing operations	170.43	347.71	(714.68)	244.37	(1,317.84)	(1,248,13)	
Profit/ (Loss) after tax - Continuing operations	118.28	347.71	(714 68)	192.22	(1.317.64)	(1,245.13)	
Profit (Loss) before tax - Discontinued operations	(189.25)	872.79	646.83	1,510.51	993.75	1,246.93	
rofit/ (Loss) after tax - Discontinued operations	(551.98)	872.79	646.83	1,147.78	993.75	1,246.93	
otal comprehensive income	(2.494.50)	(2,580.50)	1,514.74	(7,751.00)	(1,137,54)	344.90	

4a, In fine with the Company's focus on value creation in Animal Healthcare, the Board of Directors of the Company had earlier approved a scheme for demerger of Human API Business, subject to the approval from the regulatory authorities as may be necessary. The Company's application is pending with the National Company Law Tribunal (NCLT) Mumbal Bench, Under the above scheme, (which envisages an appointed date of 01 October 2017), the Company's Human API Business is proposed to be demerged into a new listed entity. During the quarter ended 31 December 2017, the shareholders of the Company in their meeting convened on 26 December 2017 pursuant to the direction of the NCLT, have approved the scheme of demerger. The Human API business has been considered as discontinued operations in these results.

4b. During the previous quarter, consequent to the approval of Board of Directors of the Company and shareholders received vide postal ballot dated 24 March 2017 for the divestment of woman healthcare business, the company has sold I transferred the business to Tenshi Life Science Private Limited, Gain on sale of business amounting to Rs, 1745 50 Lakhs is recognised and disclosed under discontinued operations.

The results relating to discontinued business are as follows:

Particulars	3 months ended 31-Dec-2017	Preceding 3 months ended 30-Sep-2017	Corresponding 3 months ended in the previous period 31-Dec-2016	Year to date figures for the current period ended 31-Dec-2017	Year to date figures for the previous period ended 31-Dec-2016	Previous year ended 31-Mar- 2017
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Total Revenue	6,593.46	8.349.83	8.968.95	25,169,16	27,466.90	35,761,09
Total Expenses	6,775.76	7,468.91	9,003.40	24.304.38	27.614.98	37,270,33
Profit/ (Loss) before exceptional item and tax. Exceptional items	(182.30)	880.92	(34.45)	854,78	(148.06)	(509.24)
Profit/ (Loss) before tax	(182.30)	880.92		-		
Gain on disposal of assets/settlement of liabilities attributable to the discontinuing operations	(102,40)	1.745 50	(34.45)	554.78	(148.05)	(509.24)
Tax Expense	362.73	1,745.50	12.82	1,745.50		
Profit (Loss) for the period	(545.03)	2,626.42	(47.27)	352.73 2.247.55	4.26 (152.32)	(520.68)

5. Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty which is now subsumed in GST. Revenue from operation for the earlier period included excise duty w

6. Tax expenses has been accrued during the current quarter based on estimated Minimum Alternate Tax applicable to the entity and has been split between continuing and discontinued operations based on book profits from

7. The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

HASKIA

CHARTERED ACCOUNTAINTS

VGALO?

Place : Thane Date : 09 February 2018

Manish G Managing Di CIEN

Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru - 560 001 Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

# INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

## TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

 We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of SEQUENT SCIENTIFIC LIMITED ("the Company"), for the quarter and nine months ended December 31, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS** 

Chartered Accountants (Firm's Registration No. 008072S)

Sathya P. Koushik

Partner

(Membership No. 206920)

Bangalore, February 09, 2018 SPK/JKS/2018

### Sequent

SEQUENT SCIENTIFIC LIMITED

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2017

					Year to date	Year to date	/Rs. in Lakh
	Particulars			Corresponding 3	figure for	figure for	1
	Laurentai2	3 months	Preceding 3	months ended in	current period	previous	Previous yes
		ended	months ended	previous period	ended	period ended	ended
		31-Dec-2017	30-Sep-2017	31-Dec-2016	31-Dec-2017	31-Dec-2016	
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	31-Mar-201
	Revenue from operations (Refer note 4)	2,672.07	2,643.83	3,024,77	8,044.09		AUDITED
	Other income	448.67	1,025.14	358.74		6,686.22	9,453 3
	Total income (I+II)	3,120,74			1,917,64	1,204.83	1,906.7
	Town the firm	3,120.74	3,668,97	3,383.51	9,961.73	7,891.05	11,360.0
/	Expenses						
	(a) Cost of materials consumed	368.65	1,013.89	947.80	4 000 50		
-	(b) Purchases of stock-in-trade	1,346.10	1,358.03		1,963.59	3,414,75	4,216,6
	(c) Changes in inventories of finished goods, stock-in-trade and work-		1,336.03	1,447.90	3,966,16	1,503.49	2,811.9
	in progress	(144,60)	137.40	40,40	(7.14)	40.82	(44.3
	(d) Excise duty on sale of goods	V a 1		86.04	100		0.00
	(e) Conversion and processing charges	414.20	105 27		122,92	280.06	381,8
	(f) Employee benefits expense	239.61		258,63	757.71	724.59	991.5
	(h) Finance costs		399 23	568,77	1,002,43	1,676.21	1,790,1
	(h) Depreciation and amortisation expense	6.41	7.24	35.51	21.81	33.30	42,3
		95.14	74.07	138 02	247.27	225.41	325 1
	(i) Other expenses	625.00	226,13	575.12	1,642.61	1,310,26	2,093 (
П	Total expenses (IV)	2,950.31	3,321.26	4,098.19	9,717.36	9,208.89	12,608.2
Ш	2002 8	1			1		
	Profit/(loss) from continuing operations before tax and	170,43	347.71	(714,68)	244,37	(1,317.84)	(1,248.1
ľ	exceptional item (III-IV)		441.01	(7.14,00)	744 21	(1,317.64)	(1,240,1
1							
ľ	Exceptional items	20	297		- 8	290.5	- 54
١	and the second of the second o				- 1		
ľ	Profit(loss) from continuing operations before tax (V-VI)	170:43	347.71	(714.68)	244.37	(1,317,84)	(1,248.1
١.			111				
	fax expense						
	a) Current tax	52 15	- 2		52.15		59
	b) Deferred tax		-	8			
ľ	fotal tax expense (VIII)	52,15		*	52.15	3	22
d.	N. Parliet. Market and A. C. Carriero	I			1		
ľ	Profit / (Loss) from continuing operation after tax (VII-VIII)	118.28	347.71	(714.68)	192.22	(1,317.84)	(1,248.1
I,	No. Feltitiana (	(10000000000000000000000000000000000000					
	Profit(Loss) from discontinued operation	(189.25)	872.79	646.83	1,510.51	993,75	1,246.9
	ax expense of discontinued operation	362.73		*	362.73		52
1	rofit/(Loss) from discontinued operation after tax (X)	(551.98)	872.79	646.83	1,147.78	993.75	1,246.9
10	traffic ( () ) ( d )	100000000000000000000000000000000000000		1500		0.000	
1	rafit / (loss) for the period (IX+X)	(433,70)	1,220.50	(67,65)	1,340.00	(324.09)	(1.2
L	When		1	1	- 1	- 1	
	ther comprehensive income			1			
	ems that will not be reclassified to profit or loss				1		
	Re-measurements of defined benefits plans	1.70	1.80	17,38	5.40	52.13	7.0
	Fair value gain / (loss) from investment in equity instruments	(2,062.60)	(08.503.6)	1,865,21	(9,096.40)	(865.58)	339 1
T	otal other comprehensive income for the period (XII)	(2,061.10)	(3,601.00)	1,882,59	(9,091.00)	(813.45)	346.1
L	CATALL STATE OF THE STATE OF TH	W12/4-013-13-00	5555555555			A. C.	
T	otal comprehensive income for the period (XI+XII)	(2,494.80)	(2,580,50)	1,814,74	(7,751.00)	(1,137.54)	344.9
L					1	*	
	armings per equity share: (Face value of Rs. 2 each) (not-	1			- 1	11	
įa.	nnualised)		- 1		- 1		
ŀ	for continuing operations		1		1		
(1	) Basic ( in Rs.)	0.05	0,14	(0.30)	0.08	(0.55)	(0.5
(2	) Diluted (in Rs.)	0.05	0.14	(0.30)	0.08	(0.55)	(0.5
l			- 1	50000		(6.7)	
-	for discontinued operations						
	) Basic ( in Rs.)	(0.23)	0,36	0.27	0.47	0.41	0.5
	Diuted (in Rs.)	(0.23)	0.36	0.27	0.47	0.41	0.5
		10000000	2.50	27	0.47	V.41	U
-	for continuing and discontinued operations	[X	1	- 1	1		
	Basic (in Rs.)	(0.18)	0.50	(0.03)	0.55	10.14	7000
	Diuted (in Rs.)	(0.18)	0,50	(0.03)	0.55	(0.14)	(0,0)
	5 · · · · · · · · · · · · · · ·	(0.10)	0.30	(0.03)	0.55	(0.14)	(0.0)

- Notes:
  The unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 09 February 2018. The statutory auditors have carried out lemited review of the financial results for the quarter and rice months ended 31 December 2017.
- 2 The Company has only one reportable segment vz. Pharmaceurocals, Accordingly, no separate disclosure of segment information has been made
- 2. The Company has only one reportable segment vs. Pharmaceurcas. Accordingly, no separate declosure or segment information has been made.
  In his with the Company facus on value creation in Animal Heathcare, the Board of Directors of the Company Law deafer approved a scheme for demerger of Human API Business, subject to the separate flat the provide from the regulator authorities as may be necessary. The Company's application is periding with the Nabonal Company Law Thumat (NCLT) Municipal Bench. Under the above scheme, (which enviseds an appointed date of 01 October 2017), the Company's Human API Business is proposed to be demerged into a new facted entity. During the quarter ended 31 December 2017, the shareholderies of the Company in their meeting convened on 26 December 2017 pursuant to the direction of the NCLT, have approved the scheme of demerger. The Human API business has been considered as discontinued operations in these results.

Particulars	3 months ended 31-Dec-2017 UNAUDITED	Preceding 3 months ended 30-Sep-2017	Corresponding 3 months ended in previous period 31-Dec-2016 UNAUDITED	Year to date figure for current period ended 31-Dec-2017 UNAUDITED	Fear to date figure for previous period ended 31-Dec-2016	Previous year ended 31-Mar-2017 AUDITED
Total Revenue Total Excenses	6 577 56 6 766 81	8 333 93 7 461 14	7 510 85 6 864 02	23,373 16 21,862,65	22 378 75 21,385.00	29.870.63 28.623.70
Profit' (Loss) before exceptional item and tax Exceptional tems	(189.25)	872.79	646.83	1,510,51	993.75	1,246,93
Profit/ (Loss) before tax Tax expense of discontinued operation	(189 25) 362 73	872,79	646,83	1,510,51 362,73	993 75	1 246 93
Profit/ (Loss) for the period	(551.98)	872.79	646.83	1,147.78	993.75	1,248.93

- 4 Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations at disclosed net of GST. Revenue from operation for the careful produced excess duly which is now subsumed in GST. Revenue from operation for the nine months ended 31 December 2017 included excess duly upto 30 June 2017. Accordingly, revenue from operation for the quarter and nine months ended 31 December 2017 are not comparable with this set of the previous periods presented.
- 5 During the previous quarter, the Company has sold investment in one of the subsidiary company. Naan Pharma Private Limited and recognised a profit of Rs. 382 88 laths under Other Income.
- 6 Tax expenses has been accrued during the current quarter based on estimated Minimum Alternate Tax applicable to the entry and has been split between continuing and discontinued operations based on book profits from the respective operations.
- 7 The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure

Place : Thane Date: 09 February 2018



Javish Wanish Gupta Managing Director

